ProCE Banner Activity

Answers to Frequently Asked Questions on State-of-the-Art Management of CLL

Clinical Thought
Read answers from an expert panel to key questions posed by an audience of healthcare professionals during a recent live CCO webinar regarding optimal management of CLL.

Released: June 30, 2021

Expiration: June 29, 2022

Share

Faculty

Jeremy S Abramson

Jeremy S Abramson, MD, MMSc

Director, Center for Lymphoma
Mass General Cancer Center
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Anthony Mato

Anthony Mato, MD, MSCE

Associate Professor
Division of Leukemia
Memorial Sloan Kettering Cancer Center
New York, New York

Provided by

Provided by National Comprehensive Cancer Network, in partnership with Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

BeiGene, Ltd.

Lilly

Pharmacyclics LLC and Janssen

Faculty Disclosure

Primary Author

Jeremy S Abramson, MD, MMSc

Director, Center for Lymphoma
Mass General Cancer Center
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Jeremy S. Abramson, MD, MMSc, has disclosed that he has received consulting fees from AstraZeneca, BeiGene, Bluebird Bio, Celgene/Bristol-Myers Squibb, Epizyme, Genentech, Genmab, Incyte, Kite, and Kymera.

Anthony Mato, MD, MSCE

Associate Professor
Division of Leukemia
Memorial Sloan Kettering Cancer Center
New York, New York

Anthony Mato, MD, MSCE, has disclosed that he has received funds for research support from AbbVie, Acerta/AstraZeneca, Adaptive, DTRM BioPharma, Johnson & Johnson, Loxo Oncology, Pharmacyclics, Regeneron, Sunesis, and TG Therapeutics and has received consulting fees from AbbVie, Acerta/AstraZeneca, Adaptive, Celgene, DTRM BioPharma, Johnson & Johnson, Pharmacyclics, Sunesis, TG Therapeutics, and Verastem.